IRLAB A — IRLAB Therapeutics AB Share News
0.000.00%
Last trade - 00:00- SEK165.12m
- SEK155.10m
- SEK57.46m
Brief: Irlab Receives Patent Expanding Patent Protection In US
Brief: Irlab Therapeutics Q1 Net Sales SEK 4.4 Mln
Brief: Irlab Provides Additional Efficacy Data From Phase IIb Study Of Pirepemat
Brief: Irlab To Initiate Study Of IRL757 In Parkinsons's Disease
Brief: Irlab Therapeutics Says Pirepemat Treatment Effect Did Not Reach Statistical Significance Compared To Placebo
Brief: IRLAB Gets Positive Feedback On Phase III Program For Mesdopetam From EMA
Brief: IRLAB Extends, Expands Debt Financing
Brief: Irlab Therapeutics Q4 Net Sales Up At Sek 42.8 Mln
Brief: IRLAB Posts Positive Topline Results From IRL757 Phase I Study
Brief: Irlab Gets Waiver From EMA About Studies With Mesdopetam In Parkinson's Disease
Brief: IRLAB Therapeutics Q3 Net Operating Loss Narrows To Sek 29.4 Mln
Brief: Irlab Gets Milestone Payment Of USD 2.5 Million
Brief: IRLAB Sees Positive Data From First Part Of Phase I Study With Drug Candidate IRL757
Brief: Irlab Granted Additional Patent For Its Drug Candidate Pirepemat
Brief: Irlab Is Granted Additional Patent For Drug Candidate Mesdopetam
Brief: IRLAB Q2 Sales SEK 42.8 Million
Brief: Irlab Appoints Kristina Torfgård As New CEO
Brief: Irlab Draws Sek 25 Mln On Previously Secured Loan Facility
Brief: IRLAB Q1 EBIT SEK -37.6 Million